Serum miR-21 as a Diagnostic and Prognostic Biomarker in Colorectal Cancer

Toiyama, Yuji; Takahashi, Masanobu; Hur, Keun; Nagasaka, Takeshi; Tanaka, Koji; Inoue, Yasuhiro; Kusunoki, Masato; Boland, C. Richard; Goel, Ajay

doi:10.1093/jnci/djt101

Cited by 423 publications

(342 citation statements)

References 40 publications

Supporting

Mentioning

327

Contrasting

Unclassified

Order By: Relevance

“…Many studies have been performed to quantify miRNAs in the blood for use as a biomarker (Table 4) [77][78][79][80][81][82][83][84][85][86][87][88] . miR-92a, located on chromosome 13q13, is a member of the miR-17-92 gene cluster.…”

Section: Mirna Biomarkers In Bloodmentioning

confidence: 99%

Advances in epigenetic biomarker research in colorectal cancer

Kuang

2014

WJG

View full text Add to dashboard Cite

Colorectal cancer (CRC) causes approximately 600000 deaths annually and is the third leading cause of cancer mortality worldwide. Despite significant advancements in treatment options, CRC patient survival is still poor owing to a lack of effective tools for early diagnosis and a limited capacity for optimal therapeutic decision making. Since there exists a need to find new biomarkers to improve diagnosis of CRC, the research on epigenetic biomarkers for molecular diagnostics encourages the translation of this field from the bench to clinical practice. Epigenetic alterations are thought to hold great promise as tumor biomarkers. In this review, we will primarily focus on recent advances in the study of epigenetic biomarkers for colorectal cancer and discuss epigenetic biomarkers, including DNA methylation, microRNA expression and histone modification, in cancer tissue, stool, plasma, serum, cell lines and xenografts. These studies have improved the chances that epigenetic biomarkers will find a place in the clinical practices of screening, early diagnosis, prognosis, therapy choice and recurrence surveillance for CRC patients. However, these studies have typically been small in size, and evaluation at a larger scale of well-controlled randomized clinical trials is the next step that is necessary to increase the quality of epigenetic biomarkers and ensure their widespread clinical use.

show abstract

Section: Mirna Biomarkers In Bloodmentioning

confidence: 99%

Advances in epigenetic biomarker research in colorectal cancer

Kuang

2014

WJG

View full text Add to dashboard Cite

show abstract

“…Several lines of evidence have suggested that miRNAs might serve as potential biomarkers for the diagnosis and prognosis of patients with colon cancer (19,(21)(22)(23).…”

Section: Discussionmentioning

confidence: 99%

“…Only a few studies have evaluated the expression levels of miRNAs after curative surgical resection of the primary tumor (21,27,28) and have looked for a diagnostic correlation between serum levels of miRNAs and post-adjuvant levels of CEA. In the present study the expression levels and the diagnostic significance of 4 circulating miRNAs (miR-17, miR-21, miR-29a and miR-92) from blood samples of colon cancer patients, who underwent radical surgery of the primary tumor and adjuvant chemotherapy were correlated with the serum levels of CEA (measured after end of adjuvant chemotherapy) and the stage of the disease.…”

Section: Discussionmentioning

confidence: 99%

“…As a result, increased level of miR-21 promotes tumor cell survival ( Figure 5). In one study it was shown that the serum levels of miR-21 statistically significantly plummeted after surgery in the subset of patients with potentially curative surgeries (21). Others demonstrated that stromal miR-21 expression was related to the expression of E-cadherin and metastasisassociated protein 1 in colorectal cancer and high miR-21 expression in stage III patients was not associated with poor DFS (32).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Serum expression levels of miR-17, miR-21, and miR-92 as potential biomarkers for recurrence after adjuvant chemotherapy in colon cancer patients

Conev

Donev

Konsoulova

et al. 2015

BST

View full text Add to dashboard Cite

“…miRNAs and their target genes can, therefore, be exploited as novel therapeutic targets and biomarkers (Figure 1). miRNA has been studied to identify differential expressions between tumors and healthy controls and in different tissue types, as well as to discover biomarkers for chemoresistance and prognosis [68][69][70][71][72] . In sarcoma research, miR-143/miR-145 cluster expression has been implicated in cancer stem cell-associated self-renewal and tumorigenicity [73] .…”

Section: Mirna Analysismentioning

confidence: 99%

The advancements of genomics and data integration in sarcoma research

et al. 2017

View full text Add to dashboard Cite

Abstract:In the age of big data, genomics and clinical research have reached a crossroads. A wealth of data is being generated, but it is becoming increasingly complicated to analyze these data to extract meaningful results. The ability to understand biological systems holistically has unprecedented potential to transform how cancers are treated. Recent major advances leading biomedical research towards "systems medicine" have been fueled by high-throughput platforms, such as microarrays and next-generation sequencing, which can capture vast amounts of data in different genomic spaces. Unfortunately, because of high dimensionality and complex relationships among these data, inferring comprehensive and useful biological models has proven computationally and statistically challenging. However, novel bioinformatic methods for data integration of cancer genomic datasets have been developed. In this review, we will describe the applications of various genomic approaches in sarcoma research and introduce bioinformatic methods for data integration. With the continuing evolution of technological and bioinformatic methodologies, the application of big data within clinics and hospitals will ultimately result in significant improvements on how cancers are detected and treated.Keywords: omics; genomics; sarcomas; sequencing; microarray; data integration; bioinformatics; big data

show abstract

Serum miR-21 as a Diagnostic and Prognostic Biomarker in Colorectal Cancer

Abstract: Serum miR-21 is a promising biomarker for the early detection and prognosis of CRC.

Cited by 423 publications

References 40 publications

Advances in epigenetic biomarker research in colorectal cancer

Advances in epigenetic biomarker research in colorectal cancer

Serum expression levels of miR-17, miR-21, and miR-92 as potential biomarkers for recurrence after adjuvant chemotherapy in colon cancer patients

The advancements of genomics and data integration in sarcoma research

Contact Info

Product

Resources

About